New Ways to Treat Diffuse Large B Cell Lymphoma
From pathogenesis to new therapeutic targets in diffuse large B cell lymphoma
This project explores the genetic differences in diffuse large B cell lymphoma to discover new treatment options for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11158782 on NIH RePORTER |
What this research studies
Diffuse Large B cell Lymphoma (DLBCL) can be challenging to treat for many patients, even with advanced therapies like CAR-T cells. A key reason for this difficulty is the wide variety in these tumors, which current classification methods don't fully capture. This project looks beyond the usual genetic analysis to focus on specific 'non-coding' parts of the DNA, called enhancers, which act like switches for genes. Researchers found that these enhancer regions are often highly mutated in DLBCL, and these mutations can prevent important genes from being properly controlled, potentially driving the cancer. By understanding these specific mutations, we hope to find new targets for medicines.
Who could benefit from this research
Good fit: This foundational research is focused on understanding the disease at a molecular level, so it is not directly recruiting patients for a clinical trial at this stage.
Not a fit: Patients without diffuse large B cell lymphoma would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could lead to new, more targeted treatments for diffuse large B cell lymphoma, especially for patients whose tumors are currently hard to classify or treat.
How similar studies have performed: This project builds on recent discoveries about hypermutated enhancer regions in DLBCL, suggesting a novel approach to understanding the disease's genetic complexity.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Dalla-Favera, Riccardo — Columbia University Health Sciences
- Study coordinator: Dalla-Favera, Riccardo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.